Verismo Therapeutics, co-founded by Michael Milone, MD, PhD, Associate Professor of Pathology and Laboratory Medicine at Penn Medicine, and Donald Siegel, MD, PhD, Professor of Pathology and Laboratory Medicine at Penn Medicine, announced the first dosing of SynKIRTM-310, a novel CAR T-cell therapy, in a patient being treated for relapsed/refractory B-cell non-Hodgkin lymphoma. This therapy has the potential to prolong T-cell persistence to combat disease relapse. Verismo aims to expand the trial and further assess SynKIRTM-310. Read more here.